The future of clinical trial funding

Slides:



Advertisements
Similar presentations
Developing an Evaluation Strategy – experience in DFID Nick York Director – Country, Corporate and Global Evaluations, World Bank IEG Former Chief Professional.
Advertisements

Line Efficiency     Percentage Month Today’s Date
Wellcome Trust/Australia/New Zealand International Collaborative Research Grants  Up to £12 million funding for Large grants to foster collaborative research.
National Health and Medical Research Council NHMRC – EU Collaborative Research Grants Scheme Dr Nick Johnson Research Programs Branch NHMRC.
SEN and Disability Green Paper Pathfinders March 2012 Update.
ESEA Flexibility U.S. Department of Education SECRETARY OF EDUCATION’S PRIORITIES.
ANNUAL REPORT TO THE COLLEGE SENATE SUNY ONEONTA MAY 7, 2012 Strategic Planning Council.
2015/2016 PSIEE Seed Grant Information Session October 21, 2015.
ProjectImpactResourcesDeadlineResourcesDeadline Forecast Plan Time Resources Risk 001xx 002xx 003xx 004xx 005xx 006xx 007xx TotalXX Example 1: Portfolio.
Research and Development Dr Julie Hankin Medical Director.
Patient and Public Involvement: Supporting a future of better research Isabelle Abbey-Vital, Research Involvement Officer.
ICT International Partnership Building in Low and Middle Income Countries (sub-Saharan Africa and ASEAN)
Jan 2016 Solar Lunar Data.
Operational Assessment of Service Delivery
Instruction This template should be used Only for The Best Employee Engagement category. Template can be modified, subject to your company template or.

Demand Management Overview Title Slide
ITI Portfolio Plan Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Current Date Visibility of ITI Projects ITI Projects.
A Review of BSC Vocabulary
Milestones & Deliverables BENE III period Jan 06 - Jun07
Q1 Jan Feb Mar ENTER TEXT HERE Notes
Coalitions for Health Improvement

Average Monthly Temperature and Rainfall
Strategic & Operational Planning:
NHMRC New Grant Program Prof Trish Livingston Associate Dean Research
RC Ohio Valley Region Strategic and Annual Planning Process January – September 2016 Notes Fr John says greeting and reflects on 75 anniversary and then.


2017 Jan Sun Mon Tue Wed Thu Fri Sat


Gantt Chart Enter Year Here Activities Jan Feb Mar Apr May Jun Jul Aug
School of Dentistry Education Research Fund (SDERF)
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Roadmap for Programme of Work


GP Portfolio Plus Supporting Nottinghamshire GPs to discover joy in their work and find a better working life #GPPortfolioPlus GP Portfolio Plus
Proposed Strategic Planning Process for FY 2013/14 thru FY 2015/16

Step 3 Step 2 Step 1 Put your text here Put your text here
MONTH CYCLE BEGINS CYCLE ENDS DUE TO FINANCE JUL /2/2015
Jan Sun Mon Tue Wed Thu Fri Sat
GEF policies: progress and next steps

Electricity Cost and Use – FY 2016 and FY 2017
Chelan-Douglas Coalition for Health Improvement


Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE


Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
The Role of Data and Analytics in the Healthcare Ecosystem
TIMELINE NAME OF PROJECT Today 2016 Jan Feb Mar Apr May Jun
Budget Planning Calendar

Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Proposed core price & service spec L1 product milestone 31 Dec 2019
Pilot of revised survey
Presentation transcript:

The future of clinical trial funding 30/30 Horizons in Healthcare Research NHMRC CTC 30th Anniversary Symposium 1 March 2019 The future of clinical trial funding Professor Anne Kelso AO Chief Executive Officer

Clinical trials funding in NHMRC’s new grant program

NHMRC’s new grant program – four streams Investigator Grants Synergy Grants Ideas Grants Strategic and leveraging grants Support the research program of outstanding investigators at all career stages Support outstanding multidisciplinary teams to work together to answer major questions that cannot be answered by a single investigator Support innovative research projects addressing a specific question Research that responds to national priorities: CREs Partnerships Development Grants Targeted Calls International schemes Clinical trials and cohort studies Salary + research support package Research costs ($5 million) One per investigator* One per investigator Two per investigator* No caps * Researchers may hold one Investigator Grant or up to two Ideas Grants

NHMRC’s new grant program – redividing the pie Old grant program New grant program Clinical Trials & Cohort Studies ~$70 million p.a.

STRATEGIC AND LEVERAGING GRANTS To support research that addresses identified national needs STRATEGIC AND LEVERAGING GRANTS Includes new scheme – Clinical Trials and Cohort Studies Objective: support high-quality clinical trials and cohort studies that address important gaps in knowledge, leading to relevant and implementable findings for the benefit of human health Open to research proposals for clinical trials and/or cohort studies of any size, including: applications for new clinical trials and/or cohort studies proposals to answer research questions using findings from existing trials or cohort studies. Criteria: Significance (40%) Research Quality (40%) Team Quality and Capability (20%) Greater visibility and no caps Focus on rationale (systematic review) Design: SPIRIT and STROBE checklists Milestone reporting

STRATEGIC AND LEVERAGING GRANTS To support research that addresses identified national needs STRATEGIC AND LEVERAGING GRANTS Includes new scheme – Clinical Trials and Cohort Studies Objective: support high-quality clinical trials and cohort studies that address important gaps in knowledge, leading to relevant and implementable findings for the benefit of human health Open to research proposals for clinical trials and/or cohort studies of any size, including: applications for new clinical trials and/or cohort studies proposals to answer research questions using findings from existing trials or cohort studies. Criteria: Significance (40%) Research Quality (40%) Team Quality and Capability (20%) Applications open 6 March 2018 Minimum data due 10 April 2019 Applications close 8 May 2019 Peer review Aug/Sep 2019

Timing of opening/closing of funding schemes in 2019 Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep CREs Development Investigator Synergy Ideas Clinical trials Postgraduate Partnership TCRs International Dementia MRFF

Medical Research Future Fund

NHMRC and MRFF budgets – to be updated 2 April 2019 Source: 2018-19 Portfolio Budget Statements

The future of clinical trial funding - practicalities NHMRC will continue to support investigator-initiated clinical trials across all disease areas. Scheme guidelines and peer review processes will need to keep up with new approaches to clinical trial design. Scheme budgets will be reviewed annually as usual. Scheme may evolve over time – please give us feedback. MRFF is focussed on government priorities, which may change over time. NHMRC will continue to deliver funding schemes (including clinical trial schemes) for MRFF at the request of Department of Health. There are opportunities for future streamlining of NHMRC and MRFF clinical trial schemes. Watch GrantConnect! Read the Guidelines!

The future of clinical trial funding – in 30 years? Funders will expect: value: clear evidence of need, potential impact and pathway to uptake end-user engagement: participant, policy maker, healthcare provider international linkages for recruitment and data sharing trial registration and open data sharing trials embedded in routine clinical practice Funders will need to provide: data inter-operability (with ethics applications, registries etc) flexibility to evaluate and fund new, more efficient trial designs more frequent/continuous funding cycles simple reporting mechanisms

Thank you